RT Journal Article
SR Electronic
T1 Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2647
DO 10.1183/13993003.congress-2015.PA2647
VO 46
IS suppl 59
A1 Yavuz Havlucu
A1 Fikret Kurhan
A1 Timur Pirildar
A1 Tugba Goktalay
A1 Aysin Sakar Coskun
A1 Pinar Celik
A1 Arzu Yorgancioglu
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/PA2647.abstract
AB ITNF-α plays a critical role in host defenses against bacterial and particularly myobacterial infections. Anti TNF-α theraphy has been used for the treatment of inflammatory diseases. Aim of this study was to assess the pulmonary infections in patients receiving anti TNF-α treatment.The data files of patients who admitted to approval for the TNF-α inhibitors treatment, were retrospectively evaluated between 2008-2014.997 patients were followed in our department during this period. 421 (42,2%) patients were male and mean age was 43,1±15,8 years. Bacterial pneumonia was seen in 35 patients candiadal pneumonia was seen in 4 patients, parasitic infection was seen in 9 patients and additionally 2 patients had pneumocystis jirovecii infection. 17 patients developed tubercolosis. Culture positive pulmonary tuberculosis occured in 9 patients, 8 patients developed extrapulmonary tuberculosis (4 tuberculosis lymphadenitis, 2 tuberculous pleurisy, 1 urogenital tuberculosis, 1 skin tuberculosis). All of patients developed tuberculosis INH prophylaxis. 59 patients of 67 patients developed infections were also using other immunosuppresive treatment with TNF-α inhibitors.Tuberculosis and pulmonary infections other than tuberculosis risk increased in patients receiving TNF-α inhibitors theraphy. The clinicians must be careful in terms of pulmonary infections other than tuberculosis in these patients.